Bristol Myers Squibb lifts 2026 revenue and profit outlook on strong Eliquis and new drug sales

Bristol Myers Squibb Eliquis 2026 revenue forecast Revlimid decline new drug sales

Bristol Myers Squibb reported second‑quarter 2026 revenue of $12.97 billion, a 6 % increase year‑on‑year and above analysts’ $11.75 billion estimate. Adjusted earnings were $2.04 per share, beating the $1.59 consensus. The company raised its full‑year revenue forecast to $49‑$50 billion, up from the prior $46‑$47.5 billion range, and lifted its adjusted 2026 earnings outlook to $6.75‑$7.00 per share, versus $6.05‑$6.35 previously. Eliquis sales reached $4.48 billion, up 22 % and the drug’s 2026 growth forecast was increased to 20‑25 % from 10‑15 %. Revlimid sales fell 49 % to $425 million, while newer products Camzyos, Reblozyl and Breyanzi generated $416 million, $735 million and $484 million respectively. Opdivo sales declined 3 % to $2.49 billion.

Entities: Accor SA · Bristol Myers Squibb · Camzyos · Eliquis · Emeis SA · Euroapi · Guillaume Bouhours · Huvepharma · Inventiva SA · Pierre Boulud · Reblozyl · Revlimid

Claims

What the coverage asserts, and how well corroborated each claim is across sources.

[○ 1 SOURCE] Veolia's first‑half 2026 revenue was €22.193 billion, up 0.8% on a comparable basis. (first-half 2026 Veolia results)
[○ 1 SOURCE] Veolia's EBITDA reached €3.552 billion in H1 2026, a 5% increase. (first-half 2026 Veolia results)
[○ 1 SOURCE] Accor's RevPAR increased 2.2% year‑on‑year in the first half of 2026. (first-half 2026 Accor results)
[○ 1 SOURCE] Accor's operating profit rose 6.5% to €563 million at constant currency in H1 2026. (first-half 2026 Accor results)
[○ 1 SOURCE] bioMérieux lowered its 2027‑28 organic revenue growth target to 3‑6%, down from 7%. (bioMérieux guidance revision 2026)
[○ 1 SOURCE] Emeis reported an occupancy rate of 89.8% in the first half of 2026. (Emeis H1 2026 performance)
[○ 1 SOURCE] Inventiva's cash and cash‑equivalents were €166.1 million as of 30 June 2026. (Inventiva H1 2026 cash position)
[○ 1 SOURCE] bioMérieux's operating profit fell 16% year‑on‑year to €313 million in H1 2026. (bioMérieux first‑half 2026 results)
[● 5 SOURCES] Bristol Myers Squibb raised its full‑year revenue guidance to $49‑$50 billion, from $46‑$47.5 billion. (2026 outlook revision)
[● 5 SOURCES] Eliquis sales in the quarter were $4.48 billion, up 22 % year‑on‑year. (Q2 2026 drug sales)
[● 5 SOURCES] The company raised its FY‑2026 adjusted earnings guidance to $6.75‑$7.00 per share, up from $6.05‑$6.35. (2026 earnings outlook)
[● 5 SOURCES] Opdivo sales fell 3 % to $2.49 billion in Q2. (Q2 2026 drug sales)